A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)

NCT07544862 · tracked via the Priya Life Science China tracker

Sponsor

Chengdu Kangnuoxing Biopharma,Inc.

Phase

Observational

Started

2026-06-02

Last updated

2026-06-10

Condition(s) studied

Atopic Dermatitis (AD)

Investigational drug(s) / intervention(s)

Stapokibart

Stapokibart: subcutaneous injection

Study summary

This study is an open label, prospective study to evaluate the safety and efficacy of Stapokibart Injection in patients with AD.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Trial participants aged 18 years or older at baseline, with no restrictions on gender. * Physician decision to treat trial participants with Stapokibart Injection for AD (according to the China-specific prescribing information) made prior to and independently of the participant's participation in the study. Exclusion Criteria: * Known history of allergic reaction to Stapokibart Injection. * Trial participants currently or plan participating in any interventional clinical trial. * Trial participants with hematologic malignancies. * Women with pregnant. * Any condition that, in the opinion of the investigator, may interfere with trial participants' ability to participate in the study.

Primary outcome measure(s)

The incidence rate of adverse reactions — From enrollment to the end of treatment at 52 weeks.
Number of Adverse Reactions is calculated based on Adverse Events and Serious Adverse Events that were assessed by the investigator as related to the study drug and categorized according to the Medical Dictionary for Regulatory Activities.

Trial sites (1)

Facility	City	Region	Status
Peking University People's Hospital	Beijing	Beijing Municipality	Recruiting

More Chengdu Kangnuoxing Biopharma,Inc. trials in China

Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid Starting soon

A Study of Stapokibart Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Active, not recruiting

Study of Stapokibart Injection in Adolescent Subjects With Seasonal Allergic Rhinitis (SAR) Starting soon

Study on the Treatment of Adolescent Patients With Seasonal Allergic Rhinitis Recruiting

A Prospective Study of Stapokibart Injection in Patients With Seasonal Allergic Rhinitis (SAR) Starting soon

Other trials for the same condition

Study of HXN6005 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis Starting soon

A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis Recruiting

The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching Starting soon

A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis Recruiting

A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07544862 on ClinicalTrials.gov ↗ ← All trials in China